Clinical Trial Update: A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

This is a Phase II, single-center trial evaluating sacituzumab govitecan in combination with pembrolizumab as neoadjuvant therapy for Stage II–III triple-negati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Yantai Yuhuangding Hospital | Conditions: Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING